Ticker

* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $107.6 million in net proceeds from the recently completed February 2026 public offering.

Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options trading activity on Friday. Investors purchased 3,011 call options on the company. This represents an increase of approximately 250% compared to the average daily volume of 861 call options. Larimar Therapeutics Stock Down 3.8% Larimar Therapeutics stock opened at $4.59

Tom Yeung here with your Sunday Digest .  In 2015, I visited the observatory at One World Trade Center – the newly opened viewing deck on the Western Hemisphere's tallest building.

Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.

BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL.